CR-CP Life Science Fund, a joint venture set up by China Resources Group and Charoen Pokphand Group, and New Science Ventures, a Connecticut and London-based venture capital firm, led a €19m Series B financing round in Novadip Biosciences, a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs. “This successful major equity financing will enable us to accelerate the development of our unique technology platform and complete a US clinical study for our lead autologous product in CPT, a rare and seriously debilitating pediatric condition. In addition to NVD-003 for CPT, we are highly excited by the clinical potential of our allogenic off the shelf NVD-X3 product as well the most recent potential applications we are now exploring in oncology. Novadip has a strong balance sheet to deliver on its strategy of progressing its highly differentiated and valuable pipeline of products for patients with clear unmet needs,” Denis Dufrane, Novadip Biosciences CEO and Co-Founder.